AIFM2 and cardiac hypertrophy: Specifically, after inhibiting FSP1, there was a significant decrease in CoQ10H2 (Figures 6B, 7B), an increase in MDA (Figures 6C, 7D), an increase in Fe2+ (Figures 6D, 7E), a greater reduction in mitochondrial membrane potential (Figure 6F), decreased cell viability, and elevated NT-proBNP (Figures 6E, 7J), increased myocardial hypertrophy (Figures 7F, G), reduced LVEF (Figures 7H, I), increased myocardial fibrosis (Figures 7K, L), and aggravated mitochondrial shrinkage and cristae fusion (Figure 7C).